Corona Remedies Ltd banner

Corona Remedies Ltd
NSE:CORONA

Watchlist Manager
Corona Remedies Ltd Logo
Corona Remedies Ltd
NSE:CORONA
Watchlist
Price: 2 083.2 INR -0.95% Market Closed
Market Cap: ₹127.4B

Wall St Price Targets

CORONA Price Targets Summary
Corona Remedies Ltd

Wall Street analysts forecast CORONA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CORONA is 2 373.54 INR with a low forecast of 2 196.75 INR and a high forecast of 2 602.95 INR.

Lowest Forecast
Price Target
2 196.75 INR
5% Upside
Average Forecast
Price Target
2 373.54 INR
14% Upside
Highest Forecast
Price Target
2 602.95 INR
25% Upside
Corona Remedies Ltd Competitors:
Price Targets

Revenue
Forecast

18% / Year
Past Growth
15% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
18% / Year
Past Growth
15% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Revenue has been 18%. The projected CAGR for the next 6 years is 15%.

Gross Profit
Forecast

20% / Year
Past Growth
17% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
20% / Year
Past Growth
17% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Gross Profit has been 20%. The projected CAGR for the next 3 years is 17%.

Operating Income
Forecast

42% / Year
Past Growth
25% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
42% / Year
Past Growth
25% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 3 years is 25%.

Pre-Tax Income
Forecast

42% / Year
Past Growth
34% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
42% / Year
Past Growth
34% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Pre-Tax Income has been 42%. The projected CAGR for the next 2 years is 34%.

Net Income
Forecast

43% / Year
Past Growth
29% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
43% / Year
Past Growth
29% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Net Income has been 43%. The projected CAGR for the next 3 years is 29%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CORONA's stock price target?
Price Target
2 373.54 INR

According to Wall Street analysts, the average 1-year price target for CORONA is 2 373.54 INR with a low forecast of 2 196.75 INR and a high forecast of 2 602.95 INR.

What is the Revenue forecast for Corona Remedies Ltd?
Projected CAGR
15%

Over the last 2 years, the compound annual growth rate for Revenue has been 18%. The projected CAGR for the next 6 years is 15%.

What is the Gross Profit forecast for Corona Remedies Ltd?
Projected CAGR
17%

Over the last 2 years, the compound annual growth rate for Gross Profit has been 20%. The projected CAGR for the next 3 years is 17%.

What is the Operating Income forecast for Corona Remedies Ltd?
Projected CAGR
25%

Over the last 2 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 3 years is 25%.

What is the Pre-Tax Income forecast for Corona Remedies Ltd?
Projected CAGR
34%

Over the last 2 years, the compound annual growth rate for Pre-Tax Income has been 42%. The projected CAGR for the next 2 years is 34%.

What is the Net Income forecast for Corona Remedies Ltd?
Projected CAGR
29%

Over the last 2 years, the compound annual growth rate for Net Income has been 43%. The projected CAGR for the next 3 years is 29%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett